Drug
Risvutatug Rezetecan
Risvutatug Rezetecan: highest development phase Phase 3, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| Risvutatug rezetecan (Ris-Rez) NCT07099898 | Phase 3 | Neoplasms, Lung |
Latest
No recent events.
Follow Risvutatug Rezetecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.